Stay updated with breaking news from Dcph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 3,750,000 shares, a growth of 10.9% from the April 30th total of 3,380,000 shares. Approximately 7.0% of the company’s stock are short sold. Based on an average […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) shares traded down 3.1% during mid-day trading on Monday . The stock traded as low as $14.32 and last traded at $14.32. 221,863 shares changed hands during trading, a decline of 71% from the average session volume of 764,351 shares. The stock had previously closed at $14.78. Analyst […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) rose 7.8% during mid-day trading on Monday following insider buying activity. The stock traded as high as $14.85 and last traded at $14.84. Approximately 51,290 shares traded hands during mid-day trading, a decline of 93% from the average daily volume of 770,578 shares. The stock had previously closed […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) Director Dennis Leo Walsh purchased 11,000 shares of Deciphera Pharmaceuticals stock in a transaction that occurred on Wednesday, May 10th. The stock was bought at an average cost of $13.86 per share, with a total value of $152,460.00. Following the completion of the transaction, the director now owns […]
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH – Get Rating) – Equities research analysts at SVB Leerink cut their Q2 2023 EPS estimates for shares of Deciphera Pharmaceuticals in a research note issued to investors on Wednesday, May 3rd. SVB Leerink analyst A. Berens now forecasts that the company will earn ($0.65) per share for the quarter, down […]